Please assess the completion status of the following clinical trial:

Trial Title: Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving febuxostat).~* Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering therapy (other than allopurinol or febuxostat).~* Has participated in a clinical study in which febuxostat was administered.~* Is completing Phase 3 Studies C02-009 or C02-010.~* Must not have experienced any serious study drug-related adverse events in the previous study.~* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study~Exclusion Criteria:~* Has had any other significant medical condition as defined by the investigator that would interfere with the treatment, safety, or compliance with the protocol.~* Is intolerant of allopurinol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): None
- Febuxostat 120 mg QD (Type: EXPERIMENTAL): None
- Allopurinol QD (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).